Safe Practice And Nursing Care Of Patients Receiving Oral Anticancer MedicinesSafe practice and nursing care of patients receiving oral anticancer medicines: a position statement from UKONS. A position statement from the UK Oncology Nursing Society (UKONS) on the safe, effective use of oral anticancer medicines was published online on 5 February 2010 by ecancermedicalscience...
Source: mnt.toStudy Shows Elderly Blacks Are More Likely To Skip Their Medication Than Whites And May Be At Greater Risk For Other Medication-Related ProblemsOlder adults experience a number of medication-related problems, including under treatment, suboptimal drugs, suboptimal dosing, and non-adherence, which can have negative effects on their quality of life...
Source: mnt.toIndividual Counseling, Religious Support Increase Contraceptive Use In Afghanistan, WHO Study FindsBirth control use in three rural areas of Afghanistan increased over an eight-month period after health workers explained the benefits of contraception in individual counseling sessions, according to a report published Monday in the World Health Organization's journal Bulletin, the AP/Yahoo! News reports. Afghanistan has one of the highest fertility rates in the world, with an average of more than six infants per woman. Awareness and use of contraception remains low among many Afghans, with about 10% of women using some form of birth control, according to UNICEF estimates...
Source: feedproxy.google.comGynecologic Oncology Group Notifies CTI That Continuation Of GOG-212 Pivotal Trial Of OPAXIO Maintenance Therapy In Ovarian Cancer Is A PriorityCell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial...
Source: feedproxy.google.com
# posted by Network @ 1:32 PM
